Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Immunocore Holdings plcNASDAQ: IMCR

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 28.5% from a year ago

Net receivables stood at $81.07M at the end of Q1 FY2026, up 28.5% from a year earlier and up 9.6% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.

Context

  • Net receivables amounted to 7.6% of total assets at the end of Q1 FY2026, up 1.4 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +28.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$81.07M+9.6% QoQ
Last fiscal yearDec 2025
$73.98M-11.0% YoY
Year agoMar 2025
$63.09M+28.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.5%——
1 year-11.0%——
3-year CAGR+9.0%——
5-year CAGR——
10-year CAGR——

Net Receivables history

Mixed currencies · from the balance sheet

Latest · FY2025
73.98M USD
Year-over-year change
-11.0%

Net Receivables vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +28.5% is the 6th highest of 11, against a peer median of +28.9%.
  • Net receivables amounts to 7.6% of total assets for IMCR, versus a peer median of 4.5%.
IMCR Competitors
Net Receivables for IMCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€245.1M EUR-83.1%-48.4%1.2%
IMCRImmunocore Holdings plcMar 2026$81.07M USD+28.5%+9.0%7.6%
IBRXImmunityBio, Inc.Sep 2026$53.6M USD+59.0%+182.5%8.8%
JANXJanux Therapeutics, Inc.Mar 2026$42.46M USD+660.3%+109.4%4.1%
XNCRXencor, Inc.Jun 2026$42.23M USD-11.2%+0.3%5.8%
IMMPImmutep LimitedDec 2025A$37.52M AUD+2426831.8%-90.4%25.5%
RCUSArcus Biosciences, Inc.Jun 2026$36M USD+80.0%-28.1%3.9%
MGNXMacroGenics, Inc.Mar 2026$10.43M USD-1.1%-38.0%4.8%
IPHAInnate Pharma S.A.Dec 2025€7.61M EUR+363.2%+34.3%12.1%
IMTXImmatics N.V.Mar 2026€4.82M EUR-26.7%+83.6%0.9%
CGENCompugen Ltd.Mar 2026$2.34M USD-25.7%-2.5%1.6%
Peer median (excluding IMCR) —+28.9%-1.1%4.5%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Cash & Equivalents321.06M402.47M350.27M455.73M467.71M
Short-term Investments000364.65M396.44M
Net Receivables33.52M57.08M48.62M83.1M73.98M
Inventory0692K3.56M5.45M6.74M
Other Current Assets(7.69M)3.62M7.68M7.9M51.87M
Total Current Assets354.58M473.98M418.48M929.86M996.74M
Property, Plant & Equipment (Net)42.56M38.78M33.82M47.74M50.25M
Goodwill00000
Intangible Assets0410000
Long-term Investments222.69K137K000
Tax Assets3.48M5.12M8.68M14.79M0
Other Non-current Assets6.44M8.75M11.45M17.12M20.28M
Total Non-current Assets52.7M52.79M53.96M79.64M70.53M
Total Assets407.28M526.76M472.44M1.01B1.07B
Account Payables10.12M14.45M14.08M25.1M24.36M
Short-term Debt00002.01M
Tax Payables718.01K1.12M1.43M00
Deferred Revenue33M7.76M00583K
Other Current Liabilities83.68K9.15M9.18M13.1M219.74M
Total Current Liabilities82.57M100.84M110.01M212.18M246.7M
Long-term Debt50.24M47.81M37.99M391.01M393.13M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.65M5.24M4.36M5.43M4.86M
Other Non-current Liabilities76.93K2.22M773.94K00
Total Non-current Liabilities93.19M87.02M70.54M436.61M439.54M
Total Liabilities175.76M187.86M180.55M648.79M686.24M
Common Stock118.77K129K83.18K135K136K
Retained Earnings(649.7M)(689.39M)(589.3M)(795.76M)(831.28M)
Accumulated OCI521.31M(54.67M)(28.7M)(33.76M)(28.08M)
Other Stockholders Equity73.36M1K23.65K1K1K
Minority Interest00000
Total Equity231.53M338.9M291.89M360.72M381.03M
Total Debt86.16M81.45M66.5M432.72M436.69M
Net Debt(234.9M)(321.02M)(283.77M)(23.01M)(31.02M)

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.